All lobbying filings

NVG, LLC

Lobbying for ACCENDRA HEALTH INC. · Global healthcare solutions company.

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$80,000.00

What the client paid this registrant for the period.

Client based in

Virginia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 2902
SOAR Act of 2025
S 1406
SOAR Act of 2025
S 4037
Diabetes Act

Lobbying activity 2

Medicare/Medicaid

Issues related to electronic prescribing, including clinical data element template for Durable Medical Equipment. Issues related to Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Competitive Bidding Updates and DMEPOS accreditation requirements in DMEPOS Calendar Year 2026 Final Rule. H.R.2902/S.1406 - Supplemental Oxygen Access Reform (SOAR) Act of 2025. S.4037 - Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services (DIABETES) Act.

Budget/Appropriations

Report language for FY2027 Appropriations related to diabetes products and the Competitive Bidding Program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.